The Motley Fool
23 Oct 2026, 09:43 UTC · 1h ago
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
Impact · against what's priced in
The article provides no new catalysts for PFE or BMY, as the identified risks—patent cliffs and payout ratios—are well-known structural headwinds. BMY's superior dividend safety relative to PFE remains a known differentiator rather than a price-moving event.
- PFE−0.20
No priced-in read yet
- In context
Pfizer's dividend payout ratio has exceeded 100% of GAAP earnings, creating a structural risk that necessitates reliance on free cash flow to avoid a cut.
Read from the article alone
Top 1 mover · tap to explore
